Qingqing Zhou

Qingqing Zhou

Auto-generated profile, based on publicly available information

Qingqing Zhou

Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2023 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
QZQingqing Zhou
Qingqing Zhou
TLTengfei Liu
Tengfei Liu
WQWenjing Qian
Wenjing Qian
JJJun Ji
Jun Ji
QCQu Cai
Qu Cai
JZJun Zhang
Jun Zhang
B cell receptor associated protein 31 (BAP31) is closely associated with tumor progression, while the role and mechanism of BAP31 in gastric cancer (GC) remains unknown. This study explored that BAP31 was upregulated in GC tissues and high expression indicated poor survival of GC patients. BAP31 knockdown inhibited cell growth and induced G1/S arrest. Moreover, BAP31 attenuation increased the lipid peroxidation level of the membrane and facilitated cellular ferroptosis. Mechanistically, BAP31 regulated cell proliferation and ferroptosis by directly binding to VDAC1 and affected VDAC1 oligomerization and polyubiquitination. HNF4A was bound to BAP31 at the promoter and increased its transcription. Furthermore, knockdown of BAP31 inclined to make GC cells vulnerable to 5-FU and ferroptosis inducer, erastin, in vivo and in vitro. Our work suggests that BAP31 may serve as prognostic factor for gastric cancer and act as potential therapeutic strategy for gastric cancer.

3 August 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
MHMuren Hu
Muren Hu
HYHongmei Yang
Hongmei Yang
SXShuai Xue
Shuai Xue
ZWZhiyuan Wang
Zhiyuan Wang
YLYangkun Li
Yangkun Li
XCXiaoxia Chen
Xiaoxia Chen
Activation of the cGAS-STING pathway represents a strategy for cancer immunotherapy. However, the efficacy of STING agonists is not only hindered by delivery barriers (poor stability and targeting), but also by tumor-intrinsic signaling dysfunctions, notably STING depletion and lactate-driven cGAS-STING pathway inhibition. Here, we develop a tumor-targeted programmable DNA nanosphere (DNS-STING-STP) that potentiates colorectal cancer immunotherapy through the restoration of STING signaling and alleviation of lactate-associated immunosuppression. DNS-STING-STP is generated via one-pot manganese-mediated rolling circle amplification, integrating interferon-stimulatory DNA motifs (ISD-dsDNA), a STING protein lacking the transmembrane (TM) domain (STINGΔTM), stiripentol, and the nucleolin-targeting AS1411 aptamer into a nanoplatform. Following nucleolin-mediated uptake, the nanoassembly exploits manganese-facilitated lysosomal escape to release its cargoes into the cytosol. Stiripentol alleviates lactate-mediated suppression of cGAS activity, while ISD-dsDNA, manganese ions, and STINGΔTM synergistically augment cGAS-STING pathway. DNS-STING-STP triggered dendritic cell maturation and cytokine secretion in vitro. In vivo, it reprogrammed the immunosuppressive tumor microenvironment by expanding effector cells (DCs, CD8+ T, NK cells) and depleting suppressive myeloid cells. Furthermore, DNS-STING-STP synergized with anti-PD-L1 blockade, resulting in colorectal tumor suppression and extended survival. Thus, this work establishes a strategy that couples targeted agonism with the correction of tumor-intrinsic cGAS-STING pathway dysfunction to amplify antitumor immunity.